Xeris Pharmaceuticals (NASDAQ: XERS) is one of 559 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Xeris Pharmaceuticals to similar companies based on the strength of its earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and valuation.
Insider and Institutional Ownership
59.4% of Xeris Pharmaceuticals shares are held by institutional investors. Comparatively, 46.2% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 7.4% of Xeris Pharmaceuticals shares are held by insiders. Comparatively, 15.4% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares Xeris Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Xeris Pharmaceuticals||$2.46 million||-$60.08 million||-2.30|
|Xeris Pharmaceuticals Competitors||$2.14 billion||$223.78 million||-4.09|
Xeris Pharmaceuticals’ competitors have higher revenue and earnings than Xeris Pharmaceuticals. Xeris Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of current ratings and price targets for Xeris Pharmaceuticals and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Xeris Pharmaceuticals Competitors||4766||13499||28289||1028||2.54|
Xeris Pharmaceuticals presently has a consensus target price of $24.50, suggesting a potential upside of 113.04%. As a group, “Pharmaceutical preparations” companies have a potential upside of 62.48%. Given Xeris Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Xeris Pharmaceuticals is more favorable than its competitors.
This table compares Xeris Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Xeris Pharmaceuticals Competitors||-1,497.56%||-835.10%||-29.73%|
Xeris Pharmaceuticals Company Profile
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that is in Phase II clinical trials for the treatment of congenital hyperinsulinism, post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, and hypoglycemia-associated autonomic failure, as well as for treating hypoglycemia associated with intermittent and chronic conditions, and bi-hormonal artificial pancreas closed-loop systems. In addition, it develops continuous subcutaneous glucagon infusion system of ready-to-use glucagon; ready-to-use diazepam formulation, which is in Phase I clinical trial for the treatment of acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is in pre-clinical stage for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.